Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled trial of Xuechan Ruanjian Rougan Tablets for liver fibrosis in chronic hepatitis B
CTR20231809Phase 2Active
- Sponsor
- Shanghai Tianchan Biotechnology
- Start
- Aug 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Xuechan Ruanjian Rougan Tablet in Chronic Hepatitis B (CHB), hepatic fibrosis, sponsored by Shanghai Tianchan Biotechnology. Started Aug 2023; status: active.
02
Drugs
Xuechan Ruanjian Rougan Tablet
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on CTR20231809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231809.